Card image cap
Pfizer licences Paxlovid to 35 generic companies globally

Thirty five generic drug makers around the world will make cheap versions of Pfizer’s  COVID-19 oral antiviral Paxlovid to supply the treatment in 95 poorer countries, according to the UN agency Medicines Patent Pool (MPP). Pfizer had struck a deal with MPP to allow generic drugmakers to make the pill for these 95 countries and it has been working since then to select the drug makers to whome they will licence. Paxlovid is expected to be an important tool in the fight against COVID-19 after it reduced hospitalizations in high-risk patients by around 90% in a clinical trial. The results were significantly better than those for Merck & Co’s rival antiviral pill molnupiravir in its clinical trial, an MPP statement said.

Elevate your practice with our advanced AI-based CDSS Tool.Transform your practice now!

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Submit a Comment